MLL3 Inhibitors

MLL3, also known as mixed-lineage leukemia 3, is a member of the MLL (mixed-lineage leukemia) family of histone lysine methyltransferases. These enzymes play critical roles in the epigenetic regulation of gene expression by catalyzing the methylation of histone proteins, particularly histone H3 lysine 4 (H3K4), a modification associated with transcriptional activation. MLL3 is involved in the deposition of mono-, di-, and trimethylation marks on H3K4, which contribute to the formation of transcriptionally permissive chromatin states necessary for the activation of gene expression programs essential for various cellular processes, including development, differentiation, and proliferation. As a key epigenetic regulator, MLL3 exerts its functions by associating with transcriptional regulatory complexes and chromatin-modifying enzymes, orchestrating the precise spatial and temporal control of gene expression patterns required for normal cellular function. The inhibition of MLL3 activity can be achieved through various mechanisms that disrupt its catalytic function, protein-protein interactions, or subcellular localization. One common strategy involves the development of small molecule inhibitors that target the catalytic SET domain of MLL3, thereby blocking its methyltransferase activity and disrupting the deposition of methyl marks on histone H3. Additionally, inhibition of protein-protein interactions essential for the formation of functional MLL3-containing complexes can disrupt its recruitment to target genes and subsequent chromatin modification. Furthermore, modulation of upstream signaling pathways or post-translational modifications that regulate MLL3 activity can also serve as effective means of inhibition. By interfering with the epigenetic regulation of gene expression mediated by MLL3, inhibition strategies offer avenues for studying the functional consequences of MLL3 dysregulation and exploring interventions targeting MLL3-associated diseases.